Form 4: Guardant Health Co-CEO Helmy Eltoukhy Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Helmy Eltoukhy, Co-CEO of Guardant Health, reports the cancellation of performance-based restricted stock units and the acquisition of new restricted stock units.
Summary
- Helmy Eltoukhy, Co-Chief Executive Officer of Guardant Health, filed a Form 4 detailing changes in beneficial ownership.
- A performance-based restricted stock unit award granted on May 26, 2020, was cancelled and forfeited on March 18, 2024, for continued employment with the company; this involved 1,130,382 units.
- Eltoukhy acquired 45,846 restricted stock units that will vest in four equal installments on the last day of each calendar quarter in 2024.
- Additionally, 286,533 restricted stock units were acquired, vesting 1/3 on January 1, 2025, and then quarterly for the remaining 24 months.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document primarily reports transactions related to executive compensation, which doesn't inherently indicate positive or negative performance. The cancellation of performance-based units is balanced by the grant of new restricted stock units.
Positives
- The forfeiture of performance-based restricted stock units was in exchange for continued employment, suggesting stability in leadership.
- The vesting schedule of the newly acquired restricted stock units incentivizes continued service and performance.
Negatives
- The cancellation of the performance-based restricted stock units could indicate a change in performance metrics or company strategy.
Risks
- Changes in executive compensation can sometimes signal internal adjustments or strategic shifts within the company.
Industry Context
Executive compensation and stock ownership are closely watched in the biotech industry, as they align management incentives with shareholder value. Changes in these arrangements can provide insights into company performance and strategic direction.
Comparison to Industry Standards
- Executive compensation packages, including restricted stock units and performance-based awards, are common in the biotech industry to attract and retain talent.
- Vesting schedules for restricted stock units typically range from 3 to 5 years, aligning with industry norms.
- Companies like Illumina and Exact Sciences also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may be interested in changes to executive compensation as it can reflect company performance and management's alignment with shareholder interests.
- Employees may view executive compensation as an indicator of the company's financial health and its commitment to rewarding leadership.
Key Dates
| Date | Description |
|---|---|
| 05/26/2020 | Date of grant for the cancelled performance-based restricted stock unit award. |
| 01/02/2021 | Date the Issuer's compensation committee certified the achievement of the stock price milestone. |
| 03/18/2024 | Date of the transaction involving the cancellation of performance-based restricted stock units and acquisition of new restricted stock units. |
| 03/31/2024 | First vesting date for one of the restricted stock unit awards. |
| 06/30/2024 | Second vesting date for one of the restricted stock unit awards. |
| 09/30/2024 | Third vesting date for one of the restricted stock unit awards. |
| 12/31/2024 | Final vesting date for one of the restricted stock unit awards. |
| 01/01/2025 | First vesting date for one of the restricted stock unit awards. |
| 05/26/2027 | Expiration date of the cancelled performance-based restricted stock units. |
| 03/22/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.